HANMI PHARM. CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 317,000 KRW | -0.78% |
|
+2.09% | -10.07% |
| May. 01 | Hanmi Pharm Q1 Profit Surges 27.5%, Sales Up 11.8% | MT |
| Mar. 19 | Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,490,741 | 4,397,245 | 3,373,870 | 3,711,167 | 4,473,421 | 4,022,134 | - | - |
| Enterprise Value (EV) 2 | 4,184 | 5,040 | 3,855 | 4,231 | 4,473 | 4,284 | 4,022 | 3,854 |
| P/E ratio | 65.7 x | 368 x | 50.3 x | 36.5 x | 30.6 x | 23.2 x | 21.1 x | 18.8 x |
| Yield | 0.17% | 0.14% | 0.18% | 0.17% | - | 0.16% | 0.16% | 0.16% |
| Capitalization / Revenue | 3.13 x | 4.09 x | 2.8 x | 2.79 x | 3 x | 2.47 x | 2.28 x | 2.31 x |
| EV / Revenue | 3.76 x | 4.68 x | 3.2 x | 3.18 x | 3 x | 2.63 x | 2.28 x | 2.22 x |
| EV / EBITDA | 26.3 x | 45.7 x | 18 x | 16.6 x | 14 x | 12.2 x | 11 x | 9.71 x |
| EV / FCF | -27.2 x | 45.9 x | 21.2 x | 32.1 x | - | 23.4 x | 19.8 x | 18.5 x |
| FCF Yield | -3.67% | 2.18% | 4.72% | 3.12% | - | 4.27% | 5.06% | 5.39% |
| Price to Book | 4.73 x | 6.02 x | 4.2 x | 4.26 x | - | 3.66 x | 3.11 x | 2.78 x |
| Nbr of stocks (in thousands) | 12,744 | 12,732 | 12,718 | 12,703 | 12,691 | 12,688 | - | - |
| Reference price 3 | 273,920 | 345,361 | 265,283 | 292,157 | 352,500 | 317,000 | 317,000 | 317,000 |
| Announcement Date | 2/7/20 | 2/4/21 | 1/27/22 | 2/8/23 | 2/2/24 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,114 | 1,076 | 1,206 | 1,332 | 1,491 | 1,627 | 1,762 | 1,738 |
| EBITDA 1 | 159.3 | 110.3 | 214.5 | 254.9 | 319.1 | 349.9 | 366.9 | 397 |
| EBIT 1 | 103.9 | 48.68 | 127.4 | 157 | 220.7 | 255.6 | 273.7 | 309.4 |
| Operating Margin | 9.33% | 4.52% | 10.56% | 11.79% | 14.8% | 15.71% | 15.53% | 17.8% |
| Earnings before Tax (EBT) 1 | 83.3 | 22.13 | 103.8 | 116.9 | 194 | 232.9 | 258.3 | 293.6 |
| Net income 1 | 52.11 | 11.96 | 81.08 | 76.93 | 159.3 | 173.4 | 188 | 215.5 |
| Net margin | 4.68% | 1.11% | 6.72% | 5.78% | 10.68% | 10.66% | 10.67% | 12.4% |
| EPS 2 | 4,170 | 939.5 | 5,270 | 7,994 | 11,522 | 13,675 | 14,998 | 16,877 |
| Free Cash Flow 3 | -153,685 | 109,719 | 181,974 | 131,890 | - | 182,715 | 203,458 | 207,838 |
| FCF margin | -13,800.71% | 10,198.36% | 15,088.37% | 9,903.76% | - | 11,230.84% | 11,545.15% | 11,957.93% |
| FCF Conversion (EBITDA) | - | 99,459.77% | 84,835.58% | 51,735.49% | - | 52,219.32% | 55,458.87% | 52,357.88% |
| FCF Conversion (Net income) | - | 917,443.51% | 224,446.95% | 171,451.1% | - | 105,361.15% | 108,201.97% | 96,444.32% |
| Dividend per Share 2 | 461.9 | 471.2 | 480.6 | 490.2 | - | 495.0 | 500.5 | 500.0 |
| Announcement Date | 2/7/20 | 2/4/21 | 1/27/22 | 2/8/23 | 2/2/24 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 303.1 | 350.5 | 321.1 | 316.5 | 342.1 | 351.3 | 361.7 | 342.7 | 364.6 | 422.4 | 403.7 | 386.1 | 400.6 | 438.5 | 422.5 |
| EBITDA 1 | - | - | - | 54.47 | 72.67 | 64.1 | 84.57 | 57.83 | - | 94.72 | 94.8 | 74.1 | 85.6 | 74.3 | - |
| EBIT 1 | 36.88 | 42.72 | 38.67 | 29.57 | 46.8 | 37.76 | 60.45 | 33.16 | 57.52 | 70.1 | 76.64 | 49.32 | 59.04 | 66.3 | 70.05 |
| Operating Margin | 12.17% | 12.19% | 12.04% | 9.34% | 13.68% | 10.75% | 16.71% | 9.67% | 15.78% | 16.6% | 18.99% | 12.77% | 14.74% | 15.12% | 16.58% |
| Earnings before Tax (EBT) 1 | 32.12 | 34.14 | 35.67 | 26.41 | 37.89 | 16.6 | 55.62 | 25.43 | 56.28 | 56.91 | 74.98 | 51.7 | 48.6 | 59.8 | 72.05 |
| Net income 1 | 23.4 | 17.47 | 19.31 | 18.02 | 25.37 | 13.61 | 43.11 | 16.06 | 54.71 | 47.45 | 55 | 38.2 | 32 | 41.8 | 37.7 |
| Net margin | 7.72% | 4.98% | 6.01% | 5.69% | 7.42% | 3.87% | 11.92% | 4.68% | 15% | 11.23% | 13.63% | 9.89% | 7.99% | 9.53% | 8.92% |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 1/27/22 | 4/27/22 | 7/18/22 | 11/1/22 | 2/8/23 | 4/26/23 | 7/28/23 | 11/1/23 | 2/2/24 | 4/30/24 | - | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 693 | 643 | 481 | 519 | - | 262 | - | - |
| Net Cash position 1 | - | - | - | - | - | - | 0.53 | 168 |
| Leverage (Debt/EBITDA) | 4.354 x | 5.825 x | 2.244 x | 2.038 x | - | 0.7476 x | - | - |
| Free Cash Flow 2 | -153,685 | 109,719 | 181,974 | 131,890 | - | 182,715 | 203,458 | 207,838 |
| ROE (net income / shareholders' equity) | 7.93% | 1.65% | 9.21% | 9.89% | 15.1% | 17.1% | 15.4% | 16.3% |
| ROA (Net income/ Total Assets) | 3.54% | 0.63% | 3.51% | 4.29% | - | 9.25% | 9.34% | 9.67% |
| Assets 1 | 1,471 | 1,898 | 2,310 | 1,794 | - | 1,876 | 2,013 | 2,228 |
| Book Value Per Share 3 | 57,930 | 57,329 | 63,128 | 68,632 | - | 86,697 | 101,768 | 114,138 |
| Cash Flow per Share 3 | 996.0 | 11,901 | 15,876 | 12,773 | - | 23,787 | 24,665 | 26,197 |
| Capex 1 | 166 | 41.8 | 19.9 | 30.4 | - | 50.7 | 60.6 | 54.7 |
| Capex / Sales | 14.92% | 3.89% | 1.65% | 2.28% | - | 3.11% | 3.44% | 3.15% |
| Announcement Date | 2/7/20 | 2/4/21 | 1/27/22 | 2/8/23 | 2/2/24 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
317,000
KRW
Average target price
408,986
KRW
Spread / Average Target
+29.02%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.07% | 2.97B | |
| +19.98% | 43.48B | |
| +20.67% | 22.65B | |
| +14.56% | 14.73B | |
| +14.32% | 13.79B | |
| +44.72% | 12.04B | |
| -8.37% | 7.08B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +11.90% | 5.47B |
- Stock Market
- Equities
- A128940 Stock
- Financials Hanmi Pharm. Co., Ltd.
